Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 9/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212403 | 0.93 | PDK4 (0.46) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL23442704 | 0.88 | PDK4 (0.39) | PDK4HTR6GRM5GRM1MAPT | |
| SCHEMBL17000128 | 0.86 | PDK4 (0.44) | PDK4HTR6GRM5GRM1MEN1 | |
| SCHEMBL612208 | 0.85 | PDK4 (0.37) | PDK4HTR6GRM5GRM1MAPT | |
| SCHEMBL14705092 | 0.84 | DRD2 (0.30) | — | |
| SCHEMBL19413525 | 0.82 | PDK4 (0.39) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL3434214 | 0.81 | STS (0.39) | PDK4HTR6MAPTMEN1KMT2A | |
| SCHEMBL1484967 | 0.81 | STS (0.34) | MAPTMEN1KMT2ASTSGPR119 | |
| SCHEMBL15598574 | 0.81 | PDK4 (0.36) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL14994967 | 0.81 | CCNT1 (0.38) | HTR6MAPTMEN1KMT2ASTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250090524-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | disclosed |
| CN-118984829-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-09-19 | — | — | US | disclosed |
| EP-4430048-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024145505-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024120378-A2 | TRIAZOLE COMPOUNDS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-13 | — | — | WO | disclosed |
| US-11999802-B2 | Compositions and methods for selective protein degradation | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | disclosed |
| WO-2023183607-A1 | CEREBLON LIGANDS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20050054683-A1 | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | HUTCHINSON DOUGLAS K (US) | 2005-03-10 | — | — | US | disclosed |
| US-6358942-B1 | MICROBIOCIDES AND BACTERICIDES FOR TREATING GRAMPOSITIVE, BACTEROIDES, CLOSTRIDIUM, MYCOBACTERIUM, STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS | PHARMACIA & UPJOHN COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6313307-B1 | DEBLOCKING, DEPROTECTING; CATALYTIC HYDROGENATION, ALKYLATION; PREPARING MICROBIOCIDES AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, MYCOBACTERIUM, AND CLOSTRIDIUM | PHARMACIA & UPJOHN COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-0856002-B1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | UPJOHN CO (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6166056-A | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | PHARMACIA (US) | 2000-12-26 | — | — | US | disclosed |
| US-6051716-A | ANTIMICROBIAL AGENTS | PHARMACIA & UPJOHN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6043266-A | MICROBIOCIDES TREATING GRAM-POSITIVE BACTERIA INFECTIONS AND PERSONS WITH AIDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| US-5968962-A | ANTIMICROBIAL AGENTS; EFFECTIVE AGAINST GRAMPOSITIVE BACTERIA | PHARMACIA & UPJOHN COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0856002-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997009328-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090524-A1 | BTK INHIBITORS | BTK, SYK, LYN | PDK4 2666/4885HTR6 4635/4885GRM5 4642/4885 |
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | CRBN, RPS27A, COPB1 | PDK4 3286/4885HTR6 4398/4885GRM5 4246/4885 |
| US-11999802-B2 | Compositions and methods for selective protein degradation | CRBN, RPS27A, COPB1 | PDK4 3286/4885HTR6 4398/4885GRM5 4246/4885 |
| US-20050054683-A1 | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | CBR1, NCOR1, RCOR1 | PDK4 1769/4885HTR6 2041/4885GRM5 2236/4885 |
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | CSF1R, CSF3R, IL15RA | PDK4 963/4885HTR6 4286/4885GRM5 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.